Search Within

Jonathan Eric Rosenberg

Formats
  1. Meeting Abstract (283)
  2. Journal Article (195)
  3. Review (18)
  4. Correspondence (10)
  5. Editorial (5)
  6. Guidelines (4)
  7. Book Section (2)
  8. Research Letter (2)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (520)
  2. Genitourinary Oncology Service (520)
  3. Solid Tumor Oncology Division (520)
  4. Department of Pathology and Laboratory Medicine (149)
  5. Surgery (140)
  6. Urology (137)

More Groups

People
  1. Dean Bajorin (204)
  2. Gopakumar Iyer (175)
  3. Hikmat Al-Ahmadie (134)
  4. Bernard Bochner (124)
  5. David Solit (114)
  6. Min Yuen Teo (75)

More People

Years
  1. 2025 (23)
  2. 2024 (36)
  3. 2023 (32)
  4. 2022 (36)
  5. 2021 (48)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (204)
  2. Annals of Oncology (42)
  3. European Urology (20)
  4. Clinical Genitourinary Cancer (18)
  5. Clinical Cancer Research (16)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (210)
  2. Oxford University Press (47)
  3. Elsevier Inc. (39)
  4. Elsevier Science, Inc. (36)
  5. Nature Publishing Group (36)
  6. American Association for Cancer Research (35)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Big data in oncology: Challenges and solutions
    Meeting Abstract

    Shah, N. J.; Bahadur, N.; Niederhausern, A.; Insinga, A.; Shah, I.; West, G.; Ahmad, H.; Martin, S.; Watson, A.; Nichols, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)
    Meeting Abstract

    Guercio, B. J.; Ratna, N.; Gavrilov, D.; Duzgol, C.; Akhlaq, M.; Teo, M. Y.; Regazzi, A. M.; Kotecha, R. R.; Funt, S. A.; Aggen, D. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data
    Meeting Abstract

    Friedlander, T. W.; Milowsky, M. I.; O'Donnell, P. H.; Petrylak, D. P.; Hoimes, C. J.; Flaig, T. W.; Mar, N.; Moon, H. H.; McKay, R. R.; Bilen, M. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H
    Meeting Abstract

    Flaig, T. W.; Rosenberg, J. E.; Hoimes, C. J.; O'Donnell, P. H.; Mar, N.; Gourdin, T. S.; Henry, S.; Bilen, M. A.; George, S.; Barata, P. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial
    Meeting Abstract

    Economides, M. P.; Milowsky, M. I.; O'Donnell, P. H.; Alva, A. S.; Kollmeier, M.; Rose, T. L.; Pitroda, S. P.; Rosenberg, J. E.; Hochman, T.; Goldberg, J. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up
    Meeting Abstract

    Gupta, S.; Rosenberg, J. E.; McKay, R. R.; Flaig, T. W.; Petrylak, D. P.; Hoimes, C. J.; Friedlander, T. W.; Bilen, M. A.; Srinivas, S.; Burgess, E. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Novel genetic subtypes of urothelial carcinoma with differential outcomes on immune checkpoint blockade
    Journal Article

    Sarfaty, M.; Golkaram, M.; Funt, S. A.; Al-Ahmadie, H.; Kaplan, S.; Song, F.; Regazzi, A.; Makarov, V.; Kuo, F.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Hypofractionated radiation therapy (Hypo-RT) for the treatment of localized bladder cancer
    Journal Article

    Moore, A.; Lobaugh, S. M.; Zhang, Z.; Rosenberg, J. E.; Iyer, G.; Teo, M. Y.; Bochner, B.; Donahue, T.; Nunez, D. A.; Dreyfuss, A.; more...
    Bladder Cancer (2023)

    Fulltext@MSK | Save
  • Scratching the surface: NECTIN-4 as a surrogate for enfortumab vedotin resistance
    Editorial

    Aggen, D. H.; Chu, C. E.; Rosenberg, J. E.
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
    Journal Article

    Matsubara, N.; Yonese, J.; Kojima, T.; Azuma, H.; Matsumoto, H.; Powles, T.; Rosenberg, J. E.; Petrylak, D. P.; Matsangou, M.; Wu, C.; more...
    Cancer Medicine (2023)

    Fulltext@MSK | Save